AstraZeneca Aktie News

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) said its experimental drug baxdrostat met the main target in a late-stage study for patients with resistant hypertension. Specifically, it showed a “statistically significant and highly clinically meaningful” reduction in blood pressure compared with a placebo.

AstraZeneca said on Tuesday its drug Baxdrostat met the main goal in a late-stage study in patients with treatment-resistant high blood pressure, or hypertension.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...

Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a deal worth up to $555 million.

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca.

AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.

AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when given early during treatment.

Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, especially from LLY and NVO, provide powerful tailwinds for the sector. Advances in oncology, hematology, and new cardiology drugs like Lp(a) inhibitors create multi-billion dollar opportunities for...